Table 2 The results of cost-effectiveness analysis
Country(time horizon) | Cost | Incremental cost | Utility value(QALY) | Incremental utility value(QALY) | ICER/QALY | WTP threshold | Cost-effective? |
|---|---|---|---|---|---|---|---|
United Kingdom(5 Years) | |||||||
Placebo | £7,364.87 | - | 4.562 | - | - | ||
Anastrozole | £11,470.08 | £4105.20 | 4.594 | 0.032 | £125,705.38 | £ 30,000 | No |
United Kingdom(12 Years) | |||||||
Placebo | £15,680.53 | - | 9.491 | - | - | ||
Anastrozole | £19,154.45 | £3473.91 | 9.909 | 0.418 | £8313.45 | £ 30,000 | YES |
United States(5 Years) | |||||||
Placebo | $11,671.55 | - | 4.605 | - | - | ||
Anastrozole | $16,096.51 | $4424.96 | 4.637 | 0.032 | $134,232.13 | $ 150,000 | YES |
United States(12 Years) | |||||||
Placebo | $23,821.30 | - | 9.491 | - | - | ||
Anastrozole | $27,516.61 | $3695.32 | 9.909 | 0.418 | $8,843.30 | $ 150,000 | YES |